Denmark starts rebuilding historic stock exchange destroyed by fire
:: April 16, 2024
:: Copenhagen, Denmark
:: April 15, 2025
:: Lars Daugaard Jepsen, Head of Reconstruction, Danish Chamber of Commerce
"Danes care about this building so very much because it's the first listed building (in Denmark). It has been a part of Danish history for 400 years and everything in (Danish) business is invented here. So we have the first national bank here, we had the first insurance company, we had the first listed company, we had the first business school, we had the first of nearly everything here. We had the first communication line to England from this very building."
The 400-year-old building, parts of which were largely destroyed in the fire last year, has been covered by an outer housing as the cleanup, planning and rebuilding of the stock exchange are to take place.
The fire that ripped through the building on April 16 destroyed parts of the historic structure. The blaze toppled the spire of the Old Stock Exchange and collapsed a large part of the roof, in scenes reminiscent of the fire that engulfed the Notre-Dame Cathedral in Paris in 2019.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
2 hours ago
- Wall Street Journal
Orsted Plans $9.4 Billion Rights Issue to Fund Offshore Wind Projects
Orsted ORSTED -0.10%decrease; red down pointing triangle plans to propose a rights issue that could raise $9.4 billion as it seeks fresh funds to continue its offshore wind construction projects. The Danish renewable-energy company said Monday it plans to offer new shares to existing shareholders, with support from the Danish state as the majority owner, to raise gross proceeds of 60 billion Danish kroner ($9.36 billion).
Bloomberg
2 hours ago
- Bloomberg
Orsted Plans $9 Billion Rights Issue to Strenghen Balance Sheet
Orsted A/S said it will conduct a rights issue to raise as much as 60 billion Danish kroner ($9.4 billion). The offering, which confirms a Bloomberg News report from Friday, will help the Danish renewable-power giant shore up its balance sheet after a challenging period in recent years. The rights issue has the support of the Danish state, which is the company's majority shareholder.
Yahoo
2 days ago
- Yahoo
Why Novo Nordisk Stock Flew Higher on Friday
Key Points An archrival's investigational obesity drug didn't perform spectacularly in a recent clinical study. Its results lagged that of Novo Nordisk's star product, Wegovy. 10 stocks we like better than Novo Nordisk › On Friday, the stock of Novo Nordisk (NYSE: NVO) continued to be affected by results from the lab the previous day. The interesting twist: It wasn't the company conducting the research. Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a mini-rally that extended into Friday; the company's share price added nearly 5% during today's session. That looked especially good next to the trajectory of the S&P 500 index, which could only manage a 0.8% increase on the day. News from the lab The previous day, that peer, Eli Lilly, reported the top-line results from a phase 3 trial of orforglipron. This is a pipeline GLP-1 drug akin to Novo Nordisk's Wegovy or Eli Lilly's own Zepbound, targeting weight loss. A key difference is that it's an oral medication, and thus easier to administer than the jabs of Wegovy and Zepbound. The company revealed that the highest dose of the medication led to an average of nearly 12% loss in body weight for the study's participants. The trial was conducted over a stretch of 72 weeks. Many analysts and pharmaceutical industry observers were expecting a higher rate: 15% or so. More than a few believe orforglipron's rate compares unfavorably to Wegovy, hence Novo Nordisk's small share-price pop. This, despite Eli Lilly's positive spin on the trial. In an interview on CNBC's Squawk Box, CEO David Ricks said that he was not disappointed with these results: "It's right on thesis for us." "The goal was to create an oral pill that was convenient and can be made at a huge scale, really, for the mass market, and had weight loss that was competitive with other single-acting GLP-1s, and that's what we've achieved," Ricks said. Weight loss for gain This may be so, but GLP-1 weight loss drugs are a duopoly at the moment, with Wegovy and Zepbound, so the segment is tight and competitive. Any advantage is large, and with this latest news, Novo Nordisk seems to be enjoying one. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Flew Higher on Friday was originally published by The Motley Fool Sign in to access your portfolio
